Leishmaniasis is a parasitic disease that presents four main clinical syndromes: cutaneous
leishmaniasis (CL), mucocutaneous leishmaniasis (MCL), visceral leishmaniasis/kala azar …

Revived analysis interests in natural products in the hope of discovering new and novel
antileishmanial drug leads have been driven partially by the increasing incidence of drug …

The state of antileishmanial chemotherapy is strongly compromised by the emergence of
drug-resistant Leishmania. The evolution of drug-resistant phenotypes has been linked to …

Leishmaniasis is a neglected disease that kills 60,000 people worldwide, and which is
caused by the protozoa Leishmania. The enzymes of the trypanothione pathway …

Human visceral leishmaniasis (VL) continues to be a life-threatening neglected tropical
disease, with close to 200 million people at risk of infection globally. Epidemics and …

Current strategies for the control of zoonotic visceral leishmaniasis (VL) rely on its efficient
diagnosis in both human and canine hosts. The most promising and cost effective approach …

Leishmania is the aethiological agent responsible for the visceral leishmaniasis, a serious
parasite-borne disease widely spread all over the World. The emergence of resistant strains …

Nanoscale self-assembly of peptide constructs represents a promising means to present
bioactive motifs to develop new functional materials. Here, we present a series of peptide …

Cutaneous leishmaniasis (CL) is a resistant form of leishmaniasis that is caused by a
parasite belonging to the genus Leishmania. FLU‐loaded microemulsions (MEs) were …

Protozoan parasites of the genus Leishmania are the causative agents of leishmaniasis, a
spectrum of a disease that threatens public health worldwide. Although next-generation …